Company intelligence / Profile preview

Crescent Therapeutics

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Crescent Biopharma is advancing a pipeline of next-generation oncology therapeutics, including a lead bispecific antibody (CR-001) targeting PD-1 and VEGF, which is expected to enter Phase 1 trials in early 2026. Two additional antibody-drug conjugates are in discovery and pre-IND stages. Proof-of-concept clinical data for CR-001 are expected in the second half of 2026. No human clinical results have yet been reported.[1][2][4][6]

Therapeutic areas: Oncology
Modalities: Bispecific antibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

Merger with GlycoMimeticsParagon Therapeutics (spinout origin)

Beyond the preview

Go deeper on Crescent Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crescent Therapeutics.

Explore the full profile